| Literature DB >> 33760971 |
Hayley F North1,2, Jason Bruggemann1,2, Vanessa Cropley3, Vaidy Swaminathan4,5, Suresh Sundram4,5,6,7, Rhoshel Lenroot1,2,8, Avril M Pereira3,7, Andrew Zalesky3, Chad Bousman3,9, Christos Pantelis3, Thomas W Weickert1,2,10, Cynthia Shannon Weickert11,12,13.
Abstract
While the biological substrates of brain and behavioural changes in persons with schizophrenia remain unclear, increasing evidence implicates that inflammation is involved. In schizophrenia, including first-episode psychosis and anti-psychotic naïve patients, there are numerous reports of increased peripheral inflammation, cognitive deficits and neuropathologies such as cortical thinning. Research defining the relationship between inflammation and schizophrenia symptomatology and neuropathology is needed. Therefore, we analysed the level of C-reactive protein (CRP), a peripheral inflammation marker, and its relationship with cognitive functioning in a cohort of 644 controls and 499 schizophrenia patients. In a subset of individuals who underwent MRI scanning (99 controls and 194 schizophrenia cases), we tested if serum CRP was associated with cortical thickness. CRP was significantly increased in schizophrenia patients compared to controls, co-varying for age, sex, overweight/obesity and diabetes (p < 0.006E-10). In schizophrenia, increased CRP was mildly associated with worse performance in attention, controlling for age, sex and education (R =- 0.15, p = 0.001). Further, increased CRP was associated with reduced cortical thickness in three regions related to attention: the caudal middle frontal, the pars opercularis and the posterior cingulate cortices, which remained significant after controlling for multiple comparisons (all p < 0.05). Together, these findings indicate that increased peripheral inflammation is associated with deficits in cognitive function and brain structure in schizophrenia, especially reduced attention and reduced cortical thickness in associated brain regions. Using CRP as a biomarker of peripheral inflammation in persons with schizophrenia may help to identify vulnerable patients and those that may benefit from adjunctive anti-inflammatory treatments.Entities:
Keywords: Biomarker; CRP; Immune system; MRI; Neuropathology; RBANS
Mesh:
Substances:
Year: 2021 PMID: 33760971 DOI: 10.1007/s00406-021-01237-z
Source DB: PubMed Journal: Eur Arch Psychiatry Clin Neurosci ISSN: 0940-1334 Impact factor: 5.270